Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

Item
http://www.wikidata.org/entity/Q34538416
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesSacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancerSafety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Etirinotecan pegol for the treatment of breast cancer.Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.
P2860

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

Item
http://www.wikidata.org/entity/Q34538416
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@ast
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@en
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@nl
type
label
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@ast
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@en
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@nl
prefLabel
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@ast
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@en
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Nonclinical pharmacokinetics a ...... or, in multiple cancer models.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P932